Celltrion Inc., of Incheon, South Korea, said new data presented at the International Conference on Malignant Lymphoma and the European League Against Rheumatism congress 2017 demonstrate that CD20-targeting antibody CT-P10 is comparable to reference Rituxan (rituximab, Roche Holding AG/Biogen Inc.) in terms of efficacy and safety in both oncology and autoimmune disease indications.